Drug, across the briefings

Trastuzumab across 12 cancers

Trastuzumab appears in 12 of the briefings; its FDA label names 3 of those diseases.

Disease	FDA label	Open Targets stage, on which gene	Trials	Active
Breast cancer	label names disease	phase 4 on ERBB2	182	51
Esophageal cancer	label names disease	phase 4 on ERBB2	35	14
Gastric cancer	label names disease	phase 4 on ERBB2	144	55
Bladder cancer		phase 4 on ERBB2	20	9
Cervical cancer		phase 4 on ERBB2	13	8
Cholangiocarcinoma		phase 4 on ERBB2	12	4
Colorectal cancer		phase 4 on ERBB2	57	29
Endometrial cancer		phase 4 on ERBB2	25	16
Gallbladder cancer		phase 4 on ERBB2	8	3
Lung cancer		phase 4 on ERBB2	58	28
Osteosarcoma		phase 4 on ERBB2	3	1
Small intestine cancer		phase 4 on ERBB2	2	0

The label column is the briefing's openFDA stage: a label whose Indications and Usage names the disease. The Open Targets column is the furthest clinical stage recorded for the drug against any gene on that briefing's target list, in any indication. Trials are ClinicalTrials.gov interventional studies naming the drug and the disease, from the briefing's trials stage; a dash means the briefing did not search this drug in that disease (it searches the drugs Open Targets lists against its own genes), which is not the same as none. Salt forms, biosimilar suffixes and formulation words are merged by the same rule the briefings use.